Literature DB >> 31935378

Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.

Abeer Al-Abdallah1, Iman Jahanbani2, Heba Mehdawi3, Rola H Ali4, Nabeel Al-Brahim5, Olusegun Mojiminiyi6, Thamradeen A Junaid7.   

Abstract

Immune escape is one of the main reasons for the rapid progression of cancer and the poor efficacy of immunotherapy. Papillary thyroid cancer (PTC) is usually accompanied by intra-tumoral lymphocytic infiltration. The mechanisms regulating this tumor associated immune response or its evasion are not well understood. The major histocompatibility complex class I chain-related proteins A (MICA) and its receptor the natural killer group 2 member D (NKG2D) are major executers of the anti-tumor defense. This work aimed to study the expression and regulation of MICA-NKG2D and its association with the lymphocytic infiltration and miRNAs in PTC. Expression of MICA and NKG2D in thyroid tissues, and in cultured primary thyroid cancer cells and lymphocytes transfected with miR-146b-5p inhibitor/mimic was tested by RT-PCR. Results were confirmed by immunofluorescence staining and confocal microscopy. MICA is expressed in malignant and benign thyroid tissues with no association with aggressive behavior. Expression of MICA and NKG2D in PTC is concomitant with the presence of tumor associated lymphocytic response and is regulated by miR-146b-5p. MiR-146b-5p indirectly downregulates NKG2D expression in cancer cells and in lymphocytes. Overexpression of miR-146b-5p in PTC down-regulates MICA expression possibly to reduce the immunogenicity of the tumor cells. Targeting of the MICA-NKG2D axis by miR-146b-5p might be one of the ways adopted by thyroid cancer cells to aid the tumor in evading the immune response. The importance of our findings resides in the potential therapeutic use of MICA, NKG2D and miRNA-146b-5p as targets or modulators to enable the immune response against cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MICA; NKG2D; Papillary thyroid carcinoma; miRNA

Year:  2020        PMID: 31935378     DOI: 10.1016/j.yexmp.2020.104379

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  4 in total

1.  MicroRNA-146b-5p/EPHA7 axis regulates cell invasion, metastasis, proliferation, and temozolomide-induced chemoresistance via regulation of IRAK4/TRAF6/NF-κB signaling pathway in aggressive pituitary adenoma.

Authors:  Xiaohui Lou; Yeyan Cai; Haijun Zheng; Yazhuo Zhang
Journal:  Histol Histopathol       Date:  2021-11-04       Impact factor: 2.303

Review 2.  MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Authors:  Maria Papaioannou; Angeliki G Chorti; Anthoula Chatzikyriakidou; Kleanthis Giannoulis; Sohail Bakkar; Theodosios S Papavramidis
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

3.  Receptor-ligand pair typing and prognostic risk model for papillary thyroid carcinoma based on single-cell sequencing.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

4.  Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer.

Authors:  Weiyu Ge; Jingyu Ma; Tiebo Mao; Haiyan Xu; Xiaofei Zhang; Shumin Li; Yongchao Wang; Jiayu Yao; Ming Yue; Feng Jiao; Yu Wang; Meng Zhuo; Ting Han; Jiong Hu; Xiao Zhang; Jiujie Cui; Liwei Wang
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.